BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 17607967)

  • 1. [Clinical importance of angiogenesis and angiogenic factors in oncohematology].
    Grosicki S; Grosicka A; HoĊ‚owiecki J
    Wiad Lek; 2007; 60(1-2):39-46. PubMed ID: 17607967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Angiogenesis and hematologic malignancy].
    Zini JM; Tobelem G
    Bull Cancer; 2007 Jul; 94 Spec No():S241-6. PubMed ID: 17846010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival.
    Loges S; Heil G; Bruweleit M; Schoder V; Butzal M; Fischer U; Gehling UM; Schuch G; Hossfeld DK; Fiedler W
    J Clin Oncol; 2005 Feb; 23(6):1109-17. PubMed ID: 15718307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia.
    Lee CY; Tien HF; Hu CY; Chou WC; Lin LI
    Br J Cancer; 2007 Oct; 97(7):877-82. PubMed ID: 17848952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia.
    Keith T; Araki Y; Ohyagi M; Hasegawa M; Yamamoto K; Kurata M; Nakagawa Y; Suzuki K; Kitagawa M
    Br J Haematol; 2007 May; 137(3):206-15. PubMed ID: 17408459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.
    Lohela M; Bry M; Tammela T; Alitalo K
    Curr Opin Cell Biol; 2009 Apr; 21(2):154-65. PubMed ID: 19230644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of angiogenesis in chronic lymphocytic leukemia.
    Letilovic T; Vrhovac R; Verstovsek S; Jaksic B; Ferrajoli A
    Cancer; 2006 Sep; 107(5):925-34. PubMed ID: 16832815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical implications of angiogenesis in the treatment of cancer.
    Aoun E; Taher A
    J Med Liban; 2002; 50(1-2):32-8. PubMed ID: 12841311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).
    Song G; Li Y; Jiang G
    Oncol Rep; 2012 Dec; 28(6):1935-44. PubMed ID: 22993103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia.
    Hou HA; Chou WC; Lin LI; Tang JL; Tseng MH; Huang CF; Yao M; Chen CY; Tsay W; Tien HF
    Leuk Res; 2008 Jun; 32(6):904-12. PubMed ID: 17904634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of angiogenesis in patients with myelodysplastic syndrome.
    Estey EH
    Best Pract Res Clin Haematol; 2004 Dec; 17(4):623-39. PubMed ID: 15494299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma.
    Konstantinou K; Yamamoto K; Ishibashi F; Mizoguchi Y; Kurata M; Nakagawa Y; Suzuki K; Sawabe M; Ohta M; Miyakoshi S; Crawley JT; Kitagawa M
    Br J Haematol; 2009 Mar; 144(5):696-704. PubMed ID: 19120365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Angiogenesis and hematological malignancies].
    Iversen PO
    Tidsskr Nor Laegeforen; 2003 Nov; 123(22):3198-200. PubMed ID: 14714007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenesis in hematologic malignancies.
    Moehler TM; Neben K; Ho AD; Goldschmidt H
    Ann Hematol; 2001 Dec; 80(12):695-705. PubMed ID: 11797109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway.
    Ribatti D
    Cancer Treat Rev; 2011 Aug; 37(5):344-52. PubMed ID: 21435792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukemias and plasma cell myeloma.
    Wiernik PH
    Cancer Chemother Biol Response Modif; 1999; 18():268-92. PubMed ID: 10800488
    [No Abstract]   [Full Text] [Related]  

  • 17. Current insights on the biology and clinical aspects of VEGF regulation.
    Birk DM; Barbato J; Mureebe L; Chaer RA
    Vasc Endovascular Surg; 2008 Dec-2009 Jan; 42(6):517-30. PubMed ID: 18799497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor.
    Mousa SA; Bergh JJ; Dier E; Rebbaa A; O'Connor LJ; Yalcin M; Aljada A; Dyskin E; Davis FB; Lin HY; Davis PJ
    Angiogenesis; 2008; 11(2):183-90. PubMed ID: 18080776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia.
    Shanafelt TD; Kay NE
    Semin Oncol; 2006 Apr; 33(2):174-85. PubMed ID: 16616064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.